Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Formulary for HMO in Maryland doesn’t have Vascepa

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Mellowmood77 Member Profile
 
Followed By 27
Posts 671
Boards Moderated 0
Alias Born 04/30/19
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 3/31/2020 9:23:01 AM
Amarin Highlights VASCEPA® (Icosapent Ethyl)-Related Data Presented at American College of Cardiology’s Annual Scientific ... GlobeNewswire Inc. - 3/31/2020 7:00:10 AM
Amarin Comments on Ruling in VASCEPA® ANDA Litigation GlobeNewswire Inc. - 3/30/2020 6:25:32 PM
Eicosapentaenoic Acid (EPA) Levels From VASCEPA® (Icosapent Ethyl) in REDUCE-IT® Strongly Correlated with Cardiovascular Ou... GlobeNewswire Inc. - 3/30/2020 11:45:10 AM
Pharmaceutical Firms Curtailing In-Person Sales Calls to Doctors Dow Jones News - 3/16/2020 2:29:00 PM
Eight Data Presentations Relevant to VASCEPA® (Icosapent Ethyl) Capsules and Persistent Cardiovascular Risk to be Presented ... GlobeNewswire Inc. - 3/16/2020 8:00:10 AM
Amarin Takes Proactive Steps to Support Public Health Priorities GlobeNewswire Inc. - 3/15/2020 1:56:22 PM
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 2/26/2020 5:24:33 PM
ALYI Trending VERY BULLISH at $0.004 with 1000% ROI Potential InvestorsHub NewsWire - 2/26/2020 8:58:36 AM
Annual Report (10-k) Edgar (US Regulatory) - 2/25/2020 4:11:55 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/25/2020 4:07:30 PM
Amarin Reports Record Fourth Quarter and Full Year 2019 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 2/25/2020 4:05:10 PM
Amarin to Present at Two Upcoming Investor Conferences GlobeNewswire Inc. - 2/20/2020 6:00:10 AM
Amarin To Report Fourth Quarter and Full Year 2019 Results and Host Conference Call on February 25, 2020 GlobeNewswire Inc. - 2/19/2020 4:15:10 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 4:25:35 PM
Amarin Honored by BioNJ with Innovator Award for VASCEPA® Development and Regulatory Approval GlobeNewswire Inc. - 2/6/2020 9:26:23 PM
Amarin Launches True To Your Heart, a Campaign to Educate People on Persistent Cardiovascular Risk GlobeNewswire Inc. - 1/13/2020 6:00:10 AM
Amarin Provides Update to Preliminary 2019 Results and Further Details on 2020 Outlook GlobeNewswire Inc. - 1/7/2020 6:00:10 AM
Amarin to Present at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. - 1/6/2020 6:00:10 AM
VASCEPA® Approved in Canada to Reduce the Risk of Cardiovascular Events GlobeNewswire Inc. - 1/2/2020 6:00:10 AM
Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk PR Newswire (US) - 12/13/2019 6:14:00 PM
Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk GlobeNewswire Inc. - 12/13/2019 4:49:07 PM
European Medicines Agency Accepts for Review Marketing Authorization Application for Amarin’s Icosapent Ethyl (Vascepa®) f... GlobeNewswire Inc. - 12/2/2019 6:00:10 AM
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist